SRR10899982
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- INFLAMMATORY_RESPONSE+0.500
- TNFA_SIGNALING_VIA_NFKB+0.500
- ALLOGRAFT_REJECTION+0.400
- APICAL_JUNCTION+0.400
- ESTROGEN_RESPONSE_EARLY+0.400
- ESTROGEN_RESPONSE_LATE+0.400
- HYPOXIA+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
Top 10 suppressed
- E2F_TARGETS-0.600
- DNA_REPAIR-0.500
- G2M_CHECKPOINT-0.500
- MYC_TARGETS_V1-0.400
- MYC_TARGETS_V2-0.400
- MITOTIC_SPINDLE-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- MTORC1_SIGNALING-0.200
- PROTEIN_SECRETION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1797296 | — | cohortMD2 | 0.955 |
| 2 | BS_478TN841 | Ganglioglioma | — | 0.934 |
| 3 | SRR1341702 | GTEX | — | 0.933 |
| 4 | s0102868 | — | — | 0.930 |
| 5 | TCGA-22-1000-01A-01R-A32Z-07 | — | cohortSQ1 | 0.928 |
| 6 | BS_T55Y4Z0Y | low-grade glioma | — | 0.925 |
| 7 | BS_W97QQYKQ | Ganglioglioma | — | 0.924 |
| 8 | SRR4296080 | — | cohortA1 | 0.921 |
| 9 | TCGA-55-7281-01A-11R-2039-07 | — | cohortA1 | 0.921 |
| 10 | 2eaa09cd-8e3e-4de9-ab96-7a290d780a01 | — | — | 0.921 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.400 | Idelalisib | — uncovered |
| HYPOXIA | 0.400 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.400 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |